Back to Blog
2025.05.01
Saluting Workers — Happy May Day!

Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.
Previous
CISCER (PAX1/JAM3) Methylation Testing: The 'Double-Insurance Scout' of Cervical Cancer Screening
Next
10th Xiangya Forum Highlights | PAX1/JAM3 CISCER Cervical Cancer Methylation Testing for Treatment Follow-Up: Multi-Center Clinical Study Results Outperform Current Clinical Detection Methods
